Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Archives of General Surgery(Electronic Edition) ›› 2022, Vol. 16 ›› Issue (02): 155-160. doi: 10.3877/cma.j.issn.1674-0793.2022.02.015

• Meta Analysis • Previous Articles    

Impact of neoadjuvant chemotherapy on patients with resectable colorectal cancer liver metastases: A Meta-analysis

Zhe Ji1, Zhanpeng Gao1, Shengli Dong1,()   

  1. 1. Department of General Surgery, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China
  • Received:2021-11-18 Online:2022-04-01 Published:2022-04-19
  • Contact: Shengli Dong

Abstract:

Objective

To evaluate the effect of neoadjuvant chemotherapy in the treatment of primary resectable colorectal liver metastases (CRLM) through Meta-analysis.

Methods

A literature search was performed in PubMed, Cochrane Library, Embase, CNKI and Wanfang databases from January 2006 to January 2021. The assessment data about patients receiving neoadjuvant chemotherapy were collected and processed using RevMan 5.4 software for Meta-analysis.

Results

A total of 6 644 patients from 12 relevant literatures were enrolled in this study, including 3 348 patients in the neoadjuvant chemotherapy group and 3 296 patients in the operation group. The 3-year disease-free survival rate of the operation group was better than that of the neoadjuvant chemotherapy group (OR=0.57, 95% CI: 0.48-0.68, P<0.001), the operative time was shorter (WMD=13, 95% CI: 12.78-13.22, P<0.001). There were no significant differences in complication rate, intrahepatic recurrence rate, length of hospital stay and 5-year overall survival rate between the two groups.

Conclusions

Neoadjuvant chemotherapy is safe for patients with initially resectable CRLM, but the long-term benefit is not obvious. Clinical risk score is a good strategy. Neoadjuvant chemotherapy may prolong the survival time of patients with high recurrence risk.

Key words: Colorectal neoplasms, Liver matastases, Chemotherapy, adjuvant, Meta-analysis

京ICP 备07035254号-20
Copyright © Chinese Archives of General Surgery(Electronic Edition), All Rights Reserved.
Tel: 020-87331056 E-mail: pwwxcma2007@126.com
Powered by Beijing Magtech Co. Ltd